Abstract | BACKGROUND: METHODS: Western blotting was used to establish expression of PPARgamma in AsPC-1 and SUIT-2 cells. AsPC-1 cells were treated with nontoxic doses of PPARgamma ligands (15d-PGJ(2), troglitazone, or rosiglitazone) and Matrigel Invasion chambers were used to assess invasion in vitro. A microarray for genes that contribute to invasion was used to investigate the antiinvasive targets of PPARgamma. Gene array results were confirmed by use of ribonuclease protection assay or Northern blotting. RESULTS: CONCLUSIONS:
|
Authors | Buckminster Farrow, Kathleen L O'Connor, Koji Hashimoto, Takeshi Iwamura, B Mark Evers |
Journal | Surgery
(Surgery)
Vol. 134
Issue 2
Pg. 206-12
(Aug 2003)
ISSN: 0039-6060 [Print] United States |
PMID | 12947319
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- 15-deoxyprostaglandin J2
- Chromans
- Integrins
- Matrix Metalloproteinase Inhibitors
- Receptors, Cytoplasmic and Nuclear
- Thiazoles
- Thiazolidinediones
- Transcription Factors
- Rosiglitazone
- Tissue Plasminogen Activator
- Troglitazone
- Prostaglandin D2
|
Topics |
- Chromans
(pharmacology)
- Humans
- Integrins
(antagonists & inhibitors)
- Matrix Metalloproteinase Inhibitors
- Neoplasm Invasiveness
(prevention & control)
- Pancreatic Neoplasms
(metabolism, pathology)
- Prostaglandin D2
(analogs & derivatives, pharmacology)
- Receptors, Cytoplasmic and Nuclear
(metabolism)
- Rosiglitazone
- Thiazoles
(pharmacology)
- Thiazolidinediones
- Tissue Plasminogen Activator
(antagonists & inhibitors)
- Transcription Factors
(metabolism)
- Troglitazone
- Tumor Cells, Cultured
|